Analysts Set Benitec Biopharma Limited (NASDAQ:BNTC) Price Target at $27.00

Shares of Benitec Biopharma Limited (NASDAQ:BNTC) have earned an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $27.00.

Several brokerages recently weighed in on BNTC. HC Wainwright restated a “buy” rating and set a $32.00 target price on shares of Benitec Biopharma in a report on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Benitec Biopharma in a report on Monday, April 20th. Wall Street Zen upgraded Benitec Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Evercore initiated coverage on Benitec Biopharma in a report on Tuesday, May 12th. They issued an “outperform” rating and a $25.00 price objective for the company. Finally, TD Cowen reiterated a “buy” rating on shares of Benitec Biopharma in a report on Monday, March 9th.

Institutional Investors Weigh In On Benitec Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of BNTC. RA Capital Management L.P. bought a new position in shares of Benitec Biopharma in the 4th quarter worth approximately $24,920,000. Suvretta Capital Management LLC raised its position in shares of Benitec Biopharma by 16.9% in the 4th quarter. Suvretta Capital Management LLC now owns 11,548,351 shares of the biotechnology company’s stock worth $155,556,000 after acquiring an additional 1,671,845 shares in the last quarter. Siren L.L.C. bought a new position in shares of Benitec Biopharma in the 4th quarter worth approximately $10,439,000. Alyeska Investment Group L.P. bought a new position in shares of Benitec Biopharma in the 4th quarter worth approximately $10,102,000. Finally, Balyasny Asset Management L.P. bought a new position in shares of Benitec Biopharma in the 4th quarter worth approximately $8,776,000. Hedge funds and other institutional investors own 52.19% of the company’s stock.

Benitec Biopharma Price Performance

Shares of BNTC stock opened at $10.99 on Thursday. The stock has a market capitalization of $377.51 million, a PE ratio of -9.64 and a beta of 0.28. Benitec Biopharma has a 1-year low of $9.85 and a 1-year high of $17.15. The business has a 50-day moving average of $11.81 and a 200 day moving average of $12.17.

Benitec Biopharma (NASDAQ:BNTC) last issued its earnings results on Thursday, May 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.03. Analysts anticipate that Benitec Biopharma will post -1.06 EPS for the current year.

Benitec Biopharma Company Profile

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.